Management and Shareholders


Michael Bachmann, Prof. Dr.

  • Director of the Institute for Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf

  • Head Radioimmunology, Helmholtz-Zentrum Dresden-Rossendorf

  • Head of Tumor Immunology, University Cancer Center (UCC), University Hospital ‘Carl Gustav Carus‘, Technische Universität Dresden

  • Deputy Head of the Working Group Tumor Immunology of the German Society for Immunology (Deutsche Gesellschaft für Immunologie, DGfI)

  • Founding shareholder of GEMoaB Monoclonals GmbH

 

Gerhard Ehninger, Prof. Dr. med.

 

 

 

 

 

 

 

 

 

  • Director of the Department of Internal Medicine I, Hematology Oncology, Gastroenterology, Infectious Diseases and Bone Marrow Transplantation, University Hospital ‘Carl Gustav Carus’ Technische Universität Dresden

  • Founding shareholder of the German Bone Marrow Donor Center (DKMS)

  • Founding shareholder of Cellex Gesellschaft für Zellgewinnung mbH

  • Board of directors Rhön Klinikum AG

  • Speaker SFB 655 „Von Zellen zu Geweben“ (special research unit for stem cell research)

  • Founding shareholder of GEMoaB Monoclonals GmbH

 

Volker Knöll (CEO)


  • CEO of Cellex Gesellschaft für Zellgewinnung mbH, CMS Cellex Medical Services GmbH, CMT Cellex Medical Transports GmbH and CPT Cellex Patient Treatment GmbH

  • Chief Executive Officer GEMoaB Monoclonals GmbH, responsible for Administration

 

Armin Ehninger, Dr. (CSO)


  • PhD at German Cancer Research Center (DKFZ), Heidelberg

  • Chief Scientific Officer GEMoaB Monoclonals GmbH

 

Elisabeth Ehninger (CEO)

  • Chief Executive Officer GEMoaB Monoclonals GmbH

 

Dias
gemoab-40.jpg
gemoab-36.jpg
gemoab-54.jpg